V617F “JAKs” up myeloproliferative signal

Slides:

Advertisements

Similar presentations

JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,

Advertisements

Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):

The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition by Angela G. Fleischman, Julia.

Benefits of JAK2 Inhibitor Therapy: Why Do They Work in Patients With and Without JAK2 Mutation Alessandro M. Vannucchi Section of Hematology, University.

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis Ross L. Levine,

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms by Pontus Lundberg, Axel Karow, Ronny Nienhold, Renate Looser,

Phenotypic and Functional Changes Induced at the Clonal Level in Hematopoietic Stem Cells After 5-Fluorouracil Treatment by Troy D. Randall, and Irving.

Age-associated changes in human hematopoietic stem cells

Ann Intern Med. 2008;149(1): doi: / Figure Legend:

Hypocholesterolemia Is Independently Associated with Decreased Survival in Patients with Primary Myelofibrosis: An Analysis of Lipid Profiles in 558 Myeloproliferative.

CALR mutations in patients with essential thrombocythemia diagnosed in childhood and adolescence by Fiorina Giona, Luciana Teofili, Sara Capodimonti, Marica.

Uncontrolled Wnt signaling causes leukemia

Hydroxyurea makes inflammation “just right”?

Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene by A.

“Vitamin hypothesis”: explanation for allergy increase?

Neonatal GATA1 mutant clones under the radar

by Timothy P. Hughes, and David M. Ross

Defects in DBA: more than meets the eye

Positioning NK-κB in multiple myeloma

Retroviral and Chemical Mutagenesis Identifies Pax5 as a Tumor Suppressor in B-Progenitor Acute Lymphoblastic Leukemia by Jinjun Dang, Charles G Mullighan,

Outcomes in Patients with Chronic Myeloid Leukemia (CML) Who Are Treated with Imatinib As Front Line Therapy by Kendra L. Sweet, Najla H Al Ali, Jeffrey.

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma Blood Volume 89(11): June 1, 1997 ©1997.

Juvenile Myelomonocytic Leukemia

BRAF inhibitor: targeted therapy in hairy cell leukemia

Rethinking bioactivity of FLT3 inhibitors

Evolution of Populations: Part I

The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity by Chloe James, Frederic.

Rebuttal to Ajioka and Kushner

Antibody-modified T cells: CARs take the front seat for hematologic malignancies by Marcela V. Maus, Stephan A. Grupp, David L. Porter, and Carl H. June.

Darwinian evolution and tiding clones in multiple myeloma

Important port for SHIP-1 at Dok-3

Cassie J. Clarke, Tessa L. Holyoake Experimental Hematology

CMV: when bad viruses turn good

Inherited DDX41 mutations: 11 genes and counting

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

Ayalew Tefferi, M.D. Mayo Clinic Proceedings

Targeting kinases in CML CLL

Risk for subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V gene mutation with a first episode of deep-vein.

Ayalew Tefferi, MD, Tiziano Barbui, MD Mayo Clinic Proceedings

by Ernest Beutler Blood Volume 98(9): November 1, 2001

VWF sequence variants: innocent until proven guilty

by Walter Zumkeller, and Stefan Burdach

Imatinib (IM) Plus Thalidomide (Thali), A Effective Combination For The Treatment Of Chronic Myeloid Leukemia (CML) Philadelphia ChromosomePositive (Ph.

Ph+ ALL: drawing strength from a benign past

David P. Steensma The Journal of Molecular Diagnostics

by R. Coleman Lindsley, and Benjamin L. Ebert

Gremlin: vexing VEGF receptor agonist

GATA2 finds its macrophage niche

Chemokines and chemokine receptors: here, there, and everywhere

To the heart of the APS puzzle

Volume 130, Issue 7, Pages (June 2006)

Activity of eltrombopag in severe aplastic anemia

Quantitative Determination of JAK2 V617F by TaqMan

Ayalew Tefferi, MD Mayo Clinic Proceedings

Pathogenesis of myeloproliferative neoplasms

Ayalew Tefferi, Pierre Noel, Curtis A. Hanson

Clonal heterogeneity as a driver of disease variability in the evolution of myeloproliferative neoplasms Janine Prick, Gerald de Haan, Anthony R. Green,

Determination of complex subclonal structures of hematological malignancies by multiplexed genotyping of blood progenitor colonies Francesca L. Nice,

Jack L. Arbiser Journal of Investigative Dermatology

Kinase signaling and targeted therapy for primary myelofibrosis

by Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A

Overcoming “aspirin resistance” in MPN

Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study by Jeffrey.

FCM and TCR γ gene rearrangement analysis in LGL leukemia.

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes by Elisa Rumi, Daniela.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Pure red cell aplasia by Robert T. Means Blood

by Wolfgang Warsch, Christoph Walz, and Veronika Sexl

How I treat essential thrombocythemia

Presentation transcript:

V617F “JAKs” up myeloproliferative signal by Ayalew Tefferi Blood Volume 106(10):3335-3336 November 15, 2005 ©2005 by American Society of Hematology

Phenotypic diversity associated with the JAK2 V617F tyrosine kinase mutation might arise from a combination of the particular myeloid progenitor compartment that is affected and specific secondary mutations that occur during clonal evolution. Phenotypic diversity associated with theJAK2V617F tyrosine kinase mutation might arise from a combination of the particular myeloid progenitor compartment that is affected and specific secondary mutations that occur during clonal evolution. Ayalew Tefferi Blood 2005;106:3335-3336 ©2005 by American Society of Hematology